Adjuvant effects of chemotherapeutics and Metformin on MFE-319 endometrial carcinoma cell line

Basit Öğe Kaydı
dc.authoridAYDEMIR, ISIL/0000-0002-4143-7319
dc.authoridKORKMAZ, Asst. Prof. Oya/0000-0003-2923-5869
dc.contributor.authorAydemir, Isil
dc.contributor.authorUluer, Elgin Turkoz
dc.contributor.authorKorkmaz, Oya
dc.contributor.authorTuglu, Mehmet Ibrahim
dc.contributor.authorInan, Sevinc
dc.date.accessioned2024-11-07T13:34:48Z
dc.date.available2024-11-07T13:34:48Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractWe aimed to investigate the cytotoxicity of Metformin, Cisplatin, and Paclitaxel on MFE-319 endometrial carcinoma cell line using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and immunocytochemistry assays. Half maximal inhibitory concentration (IC50) doses of three drugs alone and in the dual combinations were applied to the cells. Immunocytochemical method was performed for the cell survival and for phosphatidylinositol 3-kinase (PI3K), phosphorylated extracellular regulated kinases (pErk)-1/2, Akt-1, phosphorylated Akt (pAkt)-1/2/3 cell growth markers and angiogenic vascular endothelial growth factor (VEGF). Immunoreactivities were evaluated using H-score and analyzed using the one-way analysis of variance (ANOVA) test for statistics. It was found that these drugs caused a decrease in the immunoreactivities of these markers. Particularly, dual combination of Paclitaxel and Cisplatin decreased the immunoreactivities of PI3K, pErk-1/2, Akt-1, and pAkt-1/2/3. Cisplatin and Paclitaxel were more effective than Metformin; on the other hand, Metformin has been shown to enhance the efficacy of these two drugs. In vitro or in vivo further studies are needed to investigate the efficacy of these three drugs via PI3K/Akt signal pathway.
dc.identifier.doi10.47162/RJME.61.3.09
dc.identifier.endpage714
dc.identifier.issn1220-0522
dc.identifier.issn1582-4926
dc.identifier.issue3
dc.identifier.pmid33817712
dc.identifier.scopus2-s2.0-85103922022
dc.identifier.scopusqualityQ3
dc.identifier.startpage707
dc.identifier.urihttps://doi.org/10.47162/RJME.61.3.09
dc.identifier.urihttps://hdl.handle.net/11480/16161
dc.identifier.volume61
dc.identifier.wosWOS:000636791500009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherEditura Acad Romane
dc.relation.ispartofRomanian Journal of Morphology and Embryology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectCisplatin
dc.subjectendometrial carcinoma
dc.subjectMetformin
dc.subjectPI3K/Akt
dc.subjectPaclitaxel
dc.titleAdjuvant effects of chemotherapeutics and Metformin on MFE-319 endometrial carcinoma cell line
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu